ATE464065T1 - Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen - Google Patents

Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen

Info

Publication number
ATE464065T1
ATE464065T1 AT02700618T AT02700618T ATE464065T1 AT E464065 T1 ATE464065 T1 AT E464065T1 AT 02700618 T AT02700618 T AT 02700618T AT 02700618 T AT02700618 T AT 02700618T AT E464065 T1 ATE464065 T1 AT E464065T1
Authority
AT
Austria
Prior art keywords
alpha antigen
allergic
medical use
new medical
diseases
Prior art date
Application number
AT02700618T
Other languages
English (en)
Inventor
Yasuhiro Yasutomi
Hitoshi Mizutani
Original Assignee
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Kk filed Critical Maruho Kk
Application granted granted Critical
Publication of ATE464065T1 publication Critical patent/ATE464065T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02700618T 2001-02-20 2002-02-20 Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen ATE464065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001043291 2001-02-20
PCT/JP2002/001459 WO2002066055A1 (fr) 2001-02-20 2002-02-20 Nouvelle utilisation en medecine d'un antigene alpha ou d'un gene d'antigene alpha

Publications (1)

Publication Number Publication Date
ATE464065T1 true ATE464065T1 (de) 2010-04-15

Family

ID=18905480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700618T ATE464065T1 (de) 2001-02-20 2002-02-20 Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen

Country Status (7)

Country Link
US (4) US20040076639A1 (de)
EP (1) EP1369127B1 (de)
JP (1) JP4159362B2 (de)
AT (1) ATE464065T1 (de)
CA (1) CA2443502A1 (de)
DE (1) DE60235971D1 (de)
WO (1) WO2002066055A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076639A1 (en) * 2001-02-20 2004-04-22 Yasuhiro Yasutomi Novel medicinal use of alpha antigen or alpha antigen gene
JP5145550B2 (ja) * 2006-09-20 2013-02-20 国立大学法人三重大学 パラインフルエンザ２型ウイルスを用いた医薬組成物
US8045306B2 (en) * 2009-10-16 2011-10-25 Himax Technologies Limited Electrical-overstress protection circuit for an integrated circuit
US20120219582A1 (en) * 2009-11-02 2012-08-30 Mie University Intranasal spray-type tuberculosis vaccine using paramyxovirus vector

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02308793A (ja) * 1989-05-22 1990-12-21 Ajinomoto Co Inc ミコバクテリウム・カンサシ由来のα抗原
DE69027956T2 (de) * 1989-05-31 1997-03-06 Ajinomoto Kk Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
DE4422859C2 (de) * 1994-06-30 2000-10-05 Laves Arzneimittel Gmbh Wäßrige Zellextrakte aus Mykobacterien
JP4358306B2 (ja) * 1996-12-18 2009-11-04 スタンフォード ルーク リミティド 免疫系のＴｈ２活性のダウン−レギュレーションのためのマイコバクテリア・ワクチン
BR9808441A (pt) * 1997-03-28 2000-05-23 Cytoclonal Pharmaceutics Inc Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
JP4663113B2 (ja) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US20040076639A1 (en) * 2001-02-20 2004-04-22 Yasuhiro Yasutomi Novel medicinal use of alpha antigen or alpha antigen gene

Also Published As

Publication number Publication date
JP4159362B2 (ja) 2008-10-01
US7524675B2 (en) 2009-04-28
JPWO2002066055A1 (ja) 2004-06-17
US20060153880A1 (en) 2006-07-13
US20040076639A1 (en) 2004-04-22
EP1369127A4 (de) 2008-01-30
EP1369127A1 (de) 2003-12-10
DE60235971D1 (de) 2010-05-27
US20090286734A1 (en) 2009-11-19
EP1369127B1 (de) 2010-04-14
CA2443502A1 (en) 2002-08-29
US7622297B2 (en) 2009-11-24
WO2002066055A1 (fr) 2002-08-29
US20080132463A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
DK1703893T3 (da) Hidtil ukendte anti-il13-antistoffer og anvendelser deraf
NO20052928L (no) Nye kjemiske forbindelser
EP1555028A4 (de) Antiallergisches mittel, seine verwendung zur verringerung von allergien und verfahren zur verringerung von allergien
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60234523D1 (de) Alpha-amylasevariante mit veränderten eigenschaften
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
ATE386106T1 (de) Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
EP1644514A4 (de) Temperaturstabile amylase-polypeptide, für diese polypeptide codierende nukleinsäuren und verwendungen davon
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
WO2002069960A3 (en) Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
ATE464065T1 (de) Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
ATE402924T1 (de) Pyridiniumsalze und deren verwendung
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
ATE443135T1 (de) Fluoreszenzprotein und pigmentprotein
ATE324446T1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
DE60208192D1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60202679D1 (de) 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE323505T1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties